Hoffmann-la Roche Inc.

F. Hoffmann-la Roche Ag

European Molecular Biology Laboratory

Savira Pharmaceuticals Gmbh

Robert James Weikert

Shawn David Erickson

Elbert Chin

Qingjie Ding

Eric Mertz

Zhi Chen

Werner Neidhart

Helmut Heinrich Buschmann

Song Yang

Jean-Marc Plancher

Tanja Schulz-Gasch

Xingchun Han

Chungen Liang

Jianping Wang

Jing Zhang

Stephen Cusack

Nan Jiang

Yongguang Wang

Min Jiang

Stephen Deems Gabriel

Norbert Handler

Andrea Wolkerstorfer

Oliver Szolar

Chengang Zhou

Hassan Javanbakht

Zhanguo Wang

Joseph Anthony Bilotta

Franz-Ferdinand Roch

Weiya Yun

Buelent Kocer

Steven Joseph Berthel

Qiang Zhang

Feng Chi

The invention provides novel compounds having the general formula: wherein R, R, R, R, Rand Rare as described herein, compositions including the compounds and methods of using the compounds.

Dihydroquinolizinones for the treatment and prophylaxis of hepatitis B virus infection

The present invention discloses compounds of Formula I wherein the variables in Formula I are defined as described herein. Also disclosed are pharmaceutical compositions containing such compounds and methods for using the compounds of Formula I in the prevention or treatment of HCV infection. 

Antiviral compounds

The present invention relates to a compound having the general formula (V), optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, codrug, cocrystal, prodrug, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, which are useful in treating, ameloriating or preventing a viral disease. Furthermore, specific combination therapies are disclosed.

Cap/endo dual inhibitors and their use in the treatment, amelioration or prevention of a viral disease

The present invention discloses compounds of Formula I: wherein the variables in Formula I are defined as described herein. Also disclosed are pharmaceutical compositions containing such compounds and methods for using the compounds of Formula I in the prevention or treatment of HCV infection. 

This application discloses compounds according to generic Formula I: wherein all variables are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation such as rheumatoid arthritis. Also disclosed are compositions containing compounds of Formula I and at least one carrier, diluent or excipient. 

Inhibitors of bruton's tyrosine kinase

The present invention discloses compounds of Formula I: wherein the variables in Formula I are defined as described herein. Also disclosed are pharmaceutical compositions containing such compounds and methods for using the compounds of Formula I in the prevention or treatment of HCV infection.

The present invention discloses compounds of Formula (I): wherein the variables in Formula I are defined as described herein. Also disclosed are pharmaceutical compositions containing such compounds and methods for using the compounds of Formula I in the prevention or treatment of HCV infection. 

N-heteroaryl substituted aniline derivatives as HCV-antivirals

Growing community of inventors

Basel, Switzerland

Robert James Weikert